Challenges in microbiological diagnosis of invasive *Aspergillus* infections [version 1; referees: 2 approved]

Alexandre Alanio1-3, Stéphane Bretagne1-3

1Parasitology-Mycology Laboratory, Lariboisière Saint-Louis Fernand Widal hospitals, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
2Paris-Diderot, Sorbonne Paris Cité University, Paris, France
3Institut Pasteur, CNRS, Molecular Mycology Unit, Reference National Center of Invasive Mycoses and Antifungals, Paris, France

**Abstract**

Invasive aspergillosis (IA) has been increasingly reported in populations other than the historical hematology patients and there are new questions about the performance of microbiological tools. Microscopy and culture have been completed by biomarkers, either antigens or DNA, and in blood or respiratory specimens or both. First studied in hematology, the antigen galactomannan performance in serum is low in other patient populations where the pathophysiology of the infection can be different and the prevalence of IA is much lower. DNA detection with polymerase chain reaction (PCR) in blood or serum (or both) has reached a certain level of acceptance thanks to consensus methods based on real-time quantitative PCR (qPCR). When used on respiratory specimens, galactomannan and qPCR depend on standardization of the sampling and the diverse mycological procedures. Thus, culture remains the main diagnostic criterion in critically ill patients. The current trend toward more effective anti-mold prophylaxis in hematology hampers the yield of a screening strategy, as is usually performed in hematology. Therefore, circulating biomarkers as confirmatory tests should be considered and their performance should be reappraised in each new setting. The use of azole prophylaxis also raises the issue of selecting azole-resistant *Aspergillus fumigatus* isolates. Ideally, the biomarkers will be more efficient when individual genetic risks of IA are defined. Culture, though not standardized, remains a key element for the diagnosis of IA and has the advantage to easily detect molds other than *A. fumigatus*. It is still unclear whether next-generation sequencing will replace culture in the future.

**Keywords**

Aspergillosis, diagnosis, at-risk patients, fungal identification

---

**Open Peer Review**

**Referee Status:** ✓ ✓

**Invited Referees**

1. **Stephane Ranque**, Aix Marseille University, IP-TPT, France
   Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, France
2. **Jacques Meis**, Radboud University Nijmegen Medical Centre, The Netherlands
   Canisius Wilhelmina Hospital, The Netherlands

**F1000 Faculty Reviews** are commissioned from members of the prestigious F1000 Faculty. In order to make these reviews as comprehensive and accessible as possible, peer review takes place before publication; the referees are listed below, but their reports are not formally published.

**Discuss this article**

Comments (0)
Introduction

Invasive aspergillosis (IA) is the prototype of opportunistic diseases: all of the diagnostic and therapeutics difficulties are due to the fact that only the presence of the germ cannot identify the infection. To help epidemiological studies and the evaluation of therapeutic trials, the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) proposed criteria for defining IA, incorporating clinical, imaging, and microbiological items. These definitions are suitable for hematological diseases—mainly, acute leukemia and hematopoietic stem cell transplant (HSCT) recipients—and, to a lesser extent, solid organ transplantations (SOTs). However, either because clinicians of other specialties are increasingly interested in IA or because of the improvement of diagnostic means, IA is now reported in other immunocompromised patient populations, such as intensive care unit (ICU) patients, patients given anti-tumor necrosis factor (anti-TNF) therapy, patients with AIDS, as well as in hematology, in patients with chronic lymphoproliferative diseases, including multiple myeloma instead of acute leukemia. Definitions based on the EORTC/MSG criteria were not well adapted to these new populations associated with a low performance of serum galactomannan (GM) testing. The current challenges therefore are to adapt or develop new diagnostic microbiological criteria and to reassess the performance of biomarkers in these new populations.

In parallel, new therapeutic strategies (mainly, prophylaxis) in hematology are now widely used. If the expected result is a decrease of IA prevalence, a bystander effect, though also expected, is a negative impact on the performance of biomarkers, which must be reappraised. Indeed, the prevalence of the disease directly impacts the performance of any test and GM in particular. In parallel, this extensive use of prophylaxis has also shed light on the occurrence of azole-resistant Aspergillus fumigatus isolates.

New populations at risk of invasive aspergillosis

In hematology, IA is increasingly reported late after HSCT and in chronic lymphoproliferative disorders, mainly after several therapeutic interventions. In these patients, the main risk factor of IA is not a profound and prolonged neutropenia as historically reported in acute leukemia, but instead high-dose steroid therapy. When IA develops during steroid therapy, the pathology of the lesions shows little fungus and chronic inflammation and a lower chance that the antigen will reach the blood stream. This probably explains why GM is released in a lower quantity in serum when patients are not neutropenic. The value of GM screening in chronic lymphoproliferative disorders therefore needs to be reassessed.

Another new group of patients who have been reported to be at risk of IA are the critically ill patients in an ICU without malignancies or other known risk factors for IA. High-dose corticosteroids and comorbidities such as chronic obstructive pulmonary disease, liver or renal failure, and diabetes are commonly noted as well as all causes of severe sepsis. The issue underlined in these patients is the value of isolation of Aspergillus spp. from respiratory specimens given the absence of classic imaging signs such as a well-circumscribed nodule with halo or air crescent signs. A specific algorithm has recently been proposed to discriminate colonization from IA in critically ill patients with the introduction of “putative aspergillosis” as a new category. Thus, putative aspergillosis represented 38% of patients with a positive Aspergillus culture, which could represent a high number of ICU patients. The definition of putative aspergillosis relies on four criteria: an Aspergillus-positive lower respiratory tract specimen (entry condition); abnormal medical imaging; and either other host risk factors or a semi-quantitative Aspergillus-positive culture of bronchoalveolar lavage (BAL) fluid with a positive microscopy (hyphae with morphology indicative of Aspergillus sp.) and without bacterial growth. This would imply that the microbiological procedures to identify, quantify, and culture molds are similar in all microbiology laboratories, which is not the case even for hematology patients at high risk of IA. Additionally, this definition does not make any distinction between the Aspergillus species, although they do not all have the same virulence and anti-fungal susceptibility profile. Therefore, if the mycological criteria for defining IA in ICU patients are microscopy and isolation of Aspergillus spp., some consensus microbiological methods should be accepted.

In other patient populations such as patients who receive anti-TNF therapy or patients with AIDS, the incidence seems to remain low, although surveillance is always warranted. Similarly, a better index of suspicion is needed for the localizations that are not pulmonary, such as intestinal localizations, which are always difficult to diagnose.

Genetic susceptibility and environmental factors

Currently, the microbiological observations for the diagnosis of IA are analyzed among patients with a similar underlying disease with the understanding that all the patients with the same factors are similarly at risk. However, one has always observed differences between patients; some develop IA and others do not in the same environment and under the same treatment. This observation has been revisited with the current availability of large-scale genetic screening means. Some donor haplotypes in Toll-like receptor 4 were shown to be associated with an increased risk of IA in hematopoietic cell transplants from unrelated donors. More recently, single-nucleotide polymorphisms in the nuclear factor kappa B (NFκB)-related genes were not found to be associated with an increased risk of developing IA. Even if the current results are not very conclusive, this is an obvious field that needs to be investigated for a better assignment of anti-fungal drugs to patients at risk of IA. When this genetic susceptibility is better known, the meaning of the microbiological observation can be better interpreted.

Additionally, the environmental factors of the patients should be considered. Although IA occurs more often in outpatients, the different home or work environments are rarely investigated. There is now evidence that all patients do not share the same risk of inhaling pathogenic spores when returning home, yet this risk is rarely taken into consideration.

Diagnostic means

Besides direct microscopy and culture, which remain important for identification and anti-fungal susceptibility testing of the
fungus, several biomarkers have been evaluated: GM, 1,3-B-D-glucan (BDG), and Aspergillus DNA. These biomarkers have been tested in blood or serum (or both) and in respiratory specimens. The main issue for the present circulating biomarkers is their weak specificity. This weak specificity is due to the analytical performance of the tests but also to the presence of the biomarkers tested in the environment, including food, inhaled air, pharmaceutical products\textsuperscript{35,20}, or blood tubes\textsuperscript{27}.

Antibody detection has been poorly studied for IA because of the underlying immunodepression and is not considered a diagnostic criterion\textsuperscript{1}. Moreover, the assays are not standardized. Therefore, they will not be commented on here despite their major interest in chronic and allergic forms of pulmonary aspergillosis\textsuperscript{9}.

**Serum antigens: galactomannan and beta-D-glucan**

GM remains a cornerstone for the diagnosis of IA, which is far ahead of BDG, whose specificity is poor because of the pan-fungal nature of this marker\textsuperscript{25-30}. GM is a microbiological criterion for defining IA in hematology\textsuperscript{1} and SOT\textsuperscript{7} patients, but there are difficulties related to studying its performance as an evaluation tool and as a diagnostic criterion\textsuperscript{17}. GM is also used as a surrogate marker to follow the efficacy of treatment\textsuperscript{1}. The main limitation of serum GM is the high rate of false-positive results, which fall under two categories: irreproducible results and detection not related to IA. The irreproducible positive results correspond to results that are not confirmed when retested and should be considered negative\textsuperscript{17}. Confirmed positive results are technically true positive, which corresponds to either a true IA or the presence of GM from environmental sources\textsuperscript{25,30}. There is currently no means to safely discard a GM-positive result that is not related to ongoing IA based on technical artifacts. Only the analysis of intravenous drugs or parenteral nutrition prescribed and possibly the test of batches of drugs thought to contain manufactured GM can support a false positive due to infused products, mainly antibiotics processed through mold cultures\textsuperscript{27}. Otherwise, it is the analysis of the evolution of the disease and medical file records that allow discrimination between true-positive or false-positive results.

Currently, the medical performance of GM is decreasing due to the widespread use of effective anti-mold prophylaxis\textsuperscript{59}. In these conditions, the screening strategy usually proposed in hematology\textsuperscript{37} could become inefficient and would no longer be recommended\textsuperscript{59}. If it is used as confirmatory test, thresholds to define positivity could have to be reassessed for GM and also for other biomarkers. For instance, the GM positivity is 0.5 in two separate serum samples as used as a screening test, because the goals are to minimize the risk of IA and to limit the risk of overtreating, whereas the positivity threshold is at least 1.0 in BAL fluid sample to assess the diagnosis (http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM420248.pdf).

Recently, a lateral flow device (LFD) was compared with PCR and GM\textsuperscript{31}. This test is based on the detection of a new fungal antigen, an extracellular protein, using a monoclonal antibody. The best performance was achieved in combination with PCR, providing both 100% sensitivity and 100% specificity. Its main advantage should be to provide clinicians with a rapid operational result, even if PCR can be performed later as a confirmatory test.

**Polymerase chain reaction in blood/serum**

The first publications on the detection of circulating \textit{A. fumigatus} DNA appeared in the 1990s either in whole blood\textsuperscript{31} or in serum\textsuperscript{40}. However, as soon as this occurred, PCR for IA was shown to be highly challenging because of the very low amount of DNA in samples. This low amount exacerbated all of the pitfalls and limits of the PCR, mainly false positives due to previously amplified products and environmental contamination and false-negative results due to residual PCR inhibitors\textsuperscript{41}. In 2006, the European Aspergillus PCR Initiative (EAPCRI) was launched to seek proposals for a technical consensus. This consensus was possible thanks to the generalization of real-time quantitative PCR (qPCR), which dramatically reduces the risk of contamination from environmental amplicons and allows quantitative management of the amplification reaction to detect inhibition\textsuperscript{41}. Because whole blood is technically more demanding for the extraction steps, serum appears to be a better specimen\textsuperscript{42}. More recently, plasma has been shown to have a better sensitivity than serum and should be the preferred specimen\textsuperscript{42}. The performance of PCR in blood seems at least as good as GM\textsuperscript{44}, and the absence of both biomarkers (that is, GM and circulating DNA) could be sufficient to postpone anti-fungal therapy\textsuperscript{45}. As for GM, it remains unclear whether PCR should be used as a screening test\textsuperscript{46} or as a confirmatory test in light of the widespread use of anti-mold prophylaxis\textsuperscript{4}.

**Combined use of blood biomarkers**

A recent meta-analysis focused on pediatric cancer and HSCT and analyzing the biomarkers (GM, BDG, and DNA) separately concluded a poor performance of the tests, and the authors suggested combining several biomarkers for further studies\textsuperscript{47}. As soon as PCR was developed for IA diagnosis, the interest of associating GM and DNA detection was evaluated\textsuperscript{48}. Another recent meta-analysis showed that the association of both tests is highly suggestive of an active infection with a positive predictive value of 88%\textsuperscript{45}. A therapeutic strategy based on a combined surveillance of serum GM and Aspergillus DNA was shown to decrease the incidence of IA in high-risk hematological patients\textsuperscript{46}. The parallel use of GM and PCR was effective in reducing empirical anti-fungal treatment in hematology patients at high risk of IA\textsuperscript{31}. The combined use of LFD, instead of GM, and qPCR seems could be a better strategy\textsuperscript{48}.

**Biomarkers in bronchoalveolar lavage fluids**

Biomarkers in respiratory specimens are more prone to subjective interpretation than the same biomarkers in blood. Indeed, a positive mold culture from a respiratory specimen can be ascribed to infection, colonization, or simple bystander observation. To switch from culture to biomarkers does not radically change the issue. Additionally, biomarker assays are more amenable to standardization compared with the same assays in respiratory specimens.

GM has also been investigated in BAL fluids and some authors advocate the value of GM testing in the ICU\textsuperscript{46}. GM has also been evaluated in association with qPCR with the delineation of quantitative thresholds both for qPCR and for GM\textsuperscript{47}. However, to be widely accepted, these thresholds should be of similar values in
different settings. Unfortunately, the BAL procedures are highly variable between centers (for example, three lavages of 50 mL versus two lavages of 20 mL); more importantly, they are highly variable between patients according to their underlying pulmonary lesions. Therefore, there are substantial difficulties in obtaining consensus for qualitative thresholds.

The LFD described above has also been evaluated in BAL fluids. When the LFD assay was used alone in BAL of patients with hematological malignancies, the sensitivity of the LFD was moderate, around 60% to 70%, which according to the authors was possibly due to previous systemic anti-mold therapy. In another study on 133 ICU patients, including 16 patients with proven or probable IA, who had a positive culture or GM test, the sensitivity and specificity of the LFD was 80% and 81% respectively. On the other hand, 18 patients without IA had a positive LFD result, although some of them grew mold in their respiratory specimens. There is no means to decipher between LFD and other microbiological criteria which results are false-positive or false-negative. This underlines the difficulties in assessing the performance of a new assay in the absence of contributive biopsies. To overcome some limitations of using LFD alone, a different study coupled qPCR and LFD and concluded to the high performance of this strategy, as in serum, even when the patients were given systemic anti-mold therapy. Therefore, as for GM or culture, an isolated positive LFD result in respiratory specimens could be limited to decipher between colonization and true infection, and the addition of several mycological tools could improve the reliability of IA diagnosis.

Exhaled volatile organic compounds—though not, strictly speaking, an antigen—have been investigated by electronic nose technology. In vitro investigations were conclusive to distinguish A. fumigatus from Rhizopus oryzae. The authors propose additional in vivo studies.

**Fungal identification in biopsies**

Identification of species responsible for lesions in tissue is essential to adapt anti-fungal treatments. However, tissue is frequently processed for histopathology with formalin-fixed paraffin-embedded (FFPE) tissue, which hampers the molecular identification workflow because of technical issues. Fresh frozen tissue gives rise to a better yield than FFPE tissue in terms of qPCR detection as demonstrated in other molecular tests. Once the DNA is extracted from biopsies, various strategies can be used, such as testing multiple species/genera by qPCR or using sequencing of a pan-fungal barcode or microarrays, luminex-based methods, or PCR-electrospray ionization mass spectrometry.

However, pan-fungal primers can hybridize other eukaryotic DNAs. Therefore, the pan-fungal approach can be limited when tissue samples contain mainly human DNA, little fungal DNA, and potentially mixtures of fungi preventing sequencing of a single DNA barcode. The optimization of the pan-fungal primers is of utmost importance for a better representation of fungal species after PCR in complex media as in the current mycobiome studies.

**New Aspergillus species and azole resistance**

More and more, new mold species are reported as responsible for invasive infections. However, most of the reported cases are probable cases with isolation of these new species in respiratory specimens. Yet it is difficult to ascribe a new species to the pathology observed in the absence of biopsies confirming invasion. Indeed, a lot of different non-Aspergillus non-Mucorales species can be cultured from respiratory specimens in patients at risk of IA. Identification still relies on microscopy and Sanger sequencing of some barcode genes, mainly Internal Transcribed Spacer (ITS) and, but it is expected that matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry can achieve a more rapid identification as the databases associated with the apparatus become more and more complete and reliable. If these species emerge after or under azole therapy, a primary resistance is feared, such as for Mucorales, which is now more easily diagnosed using serum qPCR.

To know whether the new azole drug, isavuconazole, can have a specific role against these new species remains to be firmly established.

More challenging is the emergence of acquired azole resistance among A. fumigatus due to the wide use of azole drugs in agriculture and its therapeutic consequences. The resistance mechanism is mainly mutation in the cyp51A gene associated with tandem repeats. It is not clear whether the resistant phenotype is associated with a higher mortality because of the resistant phenotype or other factors such as delayed diagnosis. Indeed, in a mouse model, the virulence of isolates with cyp51A mutations showed reduced virulence compared with azole-susceptible isolates, even if this lower virulence was not confirmed in in vitro models. However, when the resistance incidence in a particular setting is over 10%, one can challenge azole therapy as the first-line therapy. A consequence for the microbiological laboratory is the need to conduct surveillance of this resistance, at least the surveillance of the resistant phenotype. This surveillance can be completed by searching for the mutations responsible for azole resistance, either from colonies or directly from the respiratory specimens. Searching for other mechanisms of azole resistance is more difficult and these other mechanisms, in contrast to mutations in the cyp51A gene, could be associated with higher virulence. When PCR is used to directly detect mutations in respiration specimens, the difficulty is to know the different percentages of wild-type and resistant Aspergillus, given that both can be simultaneously present.

**Culture and next-generation sequencing**

Given the uncertainties about biomarkers, culture remains an easy tool for the diagnosis of IA, as discussed earlier in ICU patients, and the detection of anti-fungal-resistant phenotypes. For the direct detection of resistance without culture, next-generation sequencing (NGS) will be more widely used to describe polymorphisms between isolates and mutations occurring during infection, in particular under anti-fungal treatments.

The main contribution of culture is not to focus on A. fumigatus but also to extend the spectrum to other mold infections. NGS has been tested in the hope of dramatically extending this spectrum.
to every species present in the sample. A first strategy is to focus on ribosomal DNA (18S, 28S, or ITS) amplification using pan-
fungal primers (metataxonomics) and to obtain operational taxo-
nomic units to describe the diversity of the fungi in a clinical 

specimen. This strategy is dependent on the choice of the prim-
ers described above for the identification of mold in biopsies[^3-^5]. Indeed, with some primer sets, the results represent the more easily 

amplified species rather than the real content of the specimen.

Another strategy, called metagenomics, is to circumvent the 

amplification with predefined primers using whole genome 

sequencing. This needs extensive bioinformatic work to trim the 

many different sequences. This strategy is of interest if the goal is to 

correlate the proportion of bacterial and fungal organisms in 

samples[^6] with a clear advantage on quantification compared with 

metataxonomics[^5]. This strategy is now compared in microbiol-

ogy with culturomics[^2]. Culturomics consists of multiplying the 

culture conditions to detect low-growth microorganisms[^9]. 

Concordance between metagenomics and culturomics is not as 
good as expected[^10], underlying the difficulties in detecting every 

microorganism using NGS. However, metagenomics seems more 

reliable than metataxonomics from the perspective of a diagnosis 

approach[^10].

Conclusions

The prognosis of IA is still dismal with an all-cause mortality 

around 40% at three months[^7-^10], and emerging azole resistance puts 

even more pressure on favorable outcome[^11]. Stress is often put on 

the development of new diagnostic tools, but given the multiplicity 
of risk factors and the ubiquity of molds in the environment, there is 

little hope that these present microbiological difficulties will vanish 

in the near future. At the very least, a parallel stress should be put on 

the knowledge of the pathophysiology of the infection and the 

individual genetic susceptibility to infection. We found, for instance, 
evidence that the DNA detected using PCR is free circulating 

DNA[^9]. This has an immediate consequence for the pre-analytical 

step before nucleic acid analysis, although we cannot rule out that 

DNA also originates from other sources, such as fungal elements 

engulfed in circulating macrophages that require a different pre-

analytical step to release fungal DNA from fungal elements.

For now, serum GM and DNA are the two most effective biomark-
ers for diagnosis, but their performance should be reappraised in 

new patient populations at risk of IA. Biomarkers in respiratory 

specimens also face difficulties in harmonizing clinical specimens. 

Biomarker evaluations will be hampered by the wide use of azole 

prophylaxis in hematology patients, which alters the kinetics of 

these biomarkers. This prophylaxis also exposes patients to IA due 
to resistant isolates and to other mold infections[^11]. Given the 

individual risk among a group of patients with similar treatments, the 
genetics underlying the susceptibility to IA should be further inves-
tigated to restrict the use of universal prophylaxis.

Competing interests

The authors declare that they have no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting 

this work.

References


fungal disease from the European Organization for Research and Treatment of 

Cancer/Invasive Fungal Infections Cooperative Group and the National 

Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ 


PubMed Abstract | Publisher Full Text | F1000 Recommendation

2. Salmon-Ceron D, Tubach F, Lortholary O, et al.: Drug-specific risk of non-
tuberculosis opportunistic infections in patients receiving anti-TNF therapy 

reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 


PubMed Abstract | Publisher Full Text | F1000 Recommendation


Diagnosis of Invasive Aspergillosis in HIV-Infected Patients, and Survival 


PubMed Abstract | Publisher Full Text


PubMed Abstract | Publisher Full Text


PubMed Abstract | Publisher Full Text | F1000 Recommendation

invasive aspergillosis in immunocompromized patients. Cochrane Database 


PubMed Abstract | Publisher Full Text


PubMed Abstract | Publisher Full Text

detection of invasive aspergillosis in hematology patients receiving 

PubMed Abstract | Publisher Full Text | F1000 Recommendation

9. Patterson TF, Thompson GR 3rd, Denning DW, et al.: Executive Summary: Practice 
Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update 


63(4): 433–42. 

PubMed Abstract | Publisher Full Text | F1000 Recommendation

invasive fungal infections in hematopoietic stem cell transplant recipients, 

2001-2006: overview of the Transplant-Associated Infection Surveillance 


PubMed Abstract | Publisher Full Text | F1000 Recommendation

11. Stergiopoulou T, Meletiadis J, Roilides E, et al.: Host-dependent patterns of 
tissue injury in invasive pulmonary aspergillosis. Am J Clin Pathol. 2007; 


PubMed Abstract | Publisher Full Text


Published Abstract | Full Free Text


Published Abstract | Full Free Text


Published Abstract | Full Free Text | F1000 Recommendation


Published Abstract | Full Free Text


Published Abstract | Full Free Text | F1000 Recommendation


Published Abstract | Full Free Text | F1000 Recommendation


Published Abstract | Full Free Text | F1000 Recommendation


Published Abstract | Full Free Text


Published Abstract | Full Free Text


Published Abstract | Full Free Text


Published Abstract | Full Free Text


Published Abstract | Full Free Text | F1000 Recommendation


Published Abstract | Full Free Text


Published Abstract | Full Free Text


Published Abstract | Full Free Text | F1000 Recommendation


Published Abstract | Full Free Text | F1000 Recommendation


Published Abstract | Full Free Text


Published Abstract | Full Free Text | F1000 Recommendation

Page 7 of 10

F1000Research 2017, 6(F1000 Faculty Rev):157 Last updated: 29 OCT 2018

PubMed Abstract | Publisher Full Text | F1000 Recommendation


PubMed Abstract | Publisher Full Text


PubMed Abstract | Publisher Full Text | F1000 Recommendation


PubMed Abstract | Publisher Full Text
Open Peer Review

Current Referee Status: ✔ ✔

Editorial Note on the Review Process
F1000 Faculty Reviews are commissioned from members of the prestigious F1000 Faculty and are edited as a service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees provide input before publication and only the final, revised version is published. The referees who approved the final version are listed with their names and affiliations but without their reports on earlier versions (any comments will already have been addressed in the published version).

The referees who approved this article are:

1 Jacques Meis Centre of Expertise in Mycology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
   Competing Interests: No competing interests were disclosed.

2 Stephane Ranque Aix Marseille University, IP-TPT, Marseille, France; Parasitologie & Mycologie, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France
   Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com